We are live on ! Find out more
ORTX

Orchard Therapeutics plc American Depositary Shares
ORTX

Delisted

ORTX was delisted on the 23rd of January, 2024.

Back to rankings

68 hedge funds and large institutions have $848M invested in Orchard Therapeutics plc American Depositary Shares in 2019 Q2 according to their latest regulatory filings, with 30 funds opening new positions, 20 increasing their positions, 7 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

500% more first-time investments, than exits

New positions opened: 30 | Existing positions closed: 5

186% more repeat investments, than reductions

Existing positions increased: 20 | Existing positions reduced: 7

58% more funds holding

Funds holding: 43 → 68 (+25)

3% less capital invested

Capital invested by funds: $875M → $848M (-$27.5M)

20% less funds holding in top 10

Funds holding in top 10: 5 → 4 (-1)

Holders
68
Holders Change
+25
Holders Change %
+58.14%
% of All Funds
1.48%
Holding in Top 10
4
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-20%
% of All Funds
0.09%
New
30
Increased
20
Reduced
7
Closed
5
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
+$35.4M
2
Artisan Partners
Artisan Partners
Wisconsin
+$29.2M
3
DM
Deerfield Management
New York
+$15.8M
4
Wellington Management Group
Wellington Management Group
Massachusetts
+$15.2M
5
VC
Vivo Capital
California
+$14.6M

Top Sellers

Rank Fund Capital Flow
1
VMI
VHCP Management III
New York
-$2.37M
2
SFM
Sphera Funds Management
Israel
-$1.59M
3
Alyeska Investment Group
Alyeska Investment Group
Illinois
-$1.02M
4
GTC
Ghost Tree Capital
New York
-$1M
5
OAM
Oxford Asset Management
United Kingdom
-$693K
Name Holding Trade Value Shares
Change 		Change in
Stake
GTC
26
Ghost Tree Capital
New York
$3.4M -$1M -5,705 -19%
Balyasny Asset Management
27
Balyasny Asset Management
Illinois
$3.21M +$4.02M +22,909 New
MIM
28
Monashee Investment Management
Massachusetts
$3.08M +$3.86M +22,000 New
AA
29
ALPS Advisors
Colorado
$2.78M +$3.49M +19,855 New
LCM
30
Laurion Capital Management
New York
$2.39M +$3M +17,084 New
PC
31
Polar Capital
United Kingdom
$2.1M +$2.63M +15,000 New
CH
32
CVI Holdings
Delaware
$1.83M +$2.29M +13,065 New
MWNA
33
Marshall Wace North America
New York
$1.83M +$2.29M +13,057 New
EU
34
Emory University
Georgia
$1.73M -$579K -3,300 -21%
BCP
35
Berylson Capital Partners
Massachusetts
$1.7M – – –
JPC
36
Jabodon PT Co
Nevada
$1.54M +$1.4M +7,950 +259%
SFM
37
Sphera Funds Management
Israel
$1.5M -$1.59M -9,036 -46%
CC
38
Casdin Capital
New York
$1.4M +$1.76M +10,000 New
TD Asset Management
39
TD Asset Management
Ontario, Canada
$1.23M +$750K +4,272 +95%
SSA
40
Schonfeld Strategic Advisors
New York
$819K +$1.03M +5,860 New
BlackRock
41
BlackRock
New York
$736K +$923K +5,259 New
PPA
42
Parametric Portfolio Associates
Washington
$715K -$110K -624 -11%
GPCM
43
Granite Point Capital Management
Massachusetts
$700K +$878K +5,000 New
Arrowstreet Capital
44
Arrowstreet Capital
Massachusetts
$563K +$707K +4,025 New
Northern Trust
45
Northern Trust
Illinois
$556K +$65K +370 +10%
CS
46
Credit Suisse
Switzerland
$497K +$623K +3,550 New
Marshall Wace
47
Marshall Wace
United Kingdom
$352K +$442K +2,518 New
MCM
48
Moore Capital Management
New York
$280K +$351K +2,000 New
OAM
49
Oxford Asset Management
United Kingdom
$275K -$693K -3,949 -67%
SLG
50
Stanley-Laman Group
Pennsylvania
$256K +$321K +1,828 New
1
2
3

ORTX Hedge Fund Activity: Q2 2019 in Review

68 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in Orchard Therapeutics plc American Depositary Shares (ORTX) for Q2 2019, worth a combined $848M — down 3.1% from $875M a quarter earlier.

Buyers outnumbered sellers: 30 funds opened new ORTX positions and 5 closed out — a net gain of 25 holders — while 20 added to existing stakes and 7 trimmed.

The largest buyer was T. Rowe Price Associates, adding an estimated $35.4M. The largest seller was VHCP Management III, cutting an estimated $2.37M.

  • 68 institutional investors held Orchard Therapeutics plc American Depositary Shares (ORTX) as of Q2 2019, up from 43 in Q1 2019.
  • Funds reported $848M of Orchard Therapeutics plc American Depositary Shares stock for Q2 2019, down 3.1% quarter-over-quarter.
  • 30 funds opened new Orchard Therapeutics plc American Depositary Shares positions in Q2 2019 and 5 closed out, a net change of +25 holders.
  • The largest Orchard Therapeutics plc American Depositary Shares buyer in Q2 2019 was T. Rowe Price Associates, an estimated $35.4M added.
  • The largest Orchard Therapeutics plc American Depositary Shares seller in Q2 2019 was VHCP Management III, an estimated $2.37M sold.

Based on aggregated 13F filings for Q2 2019.